Genomic Health Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 3,000 shares of Genomic Health stock in a transaction dated Thursday, October 6th. The shares were sold at an average price of $29.68, for a total transaction of $89,040.00. The sale was disclosed in a filing with the SEC, which is available through this link.
James J. Vaughn also recently made the following trade(s):
- On Monday, August 8th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The shares were sold at an average price of $28.74, for a total transaction of $86,220.00.
Genomic Health Inc. (NASDAQ:GHDX) opened at 28.91 on Thursday. Genomic Health Inc. has a 1-year low of $20.05 and a 1-year high of $35.79. The firm’s market capitalization is $964.03 million. The company has a 50 day moving average of $28.21 and a 200 day moving average of $27.28.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18). Genomic Health had a negative return on equity of 21.02% and a negative net margin of 8.84%. The business had revenue of $81.97 million for the quarter, compared to analysts’ expectations of $81.27 million. During the same period last year, the business earned ($0.29) EPS. The business’s revenue was up 16.1% on a year-over-year basis. On average, equities research analysts anticipate that Genomic Health Inc. will post ($0.47) earnings per share for the current year.
Several research firms have weighed in on GHDX. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, August 4th. Canaccord Genuity restated a “buy” rating and set a $38.00 price objective on shares of Genomic Health in a report on Friday, August 5th. Leerink Swann restated a “buy” rating on shares of Genomic Health in a report on Tuesday, June 21st. Jefferies Group boosted their price objective on shares of Genomic Health from $25.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, August 17th. Finally, Bank of America Corp. set a $28.00 price objective on shares of Genomic Health and gave the company a “sell” rating in a report on Wednesday, August 3rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $32.50.
A number of institutional investors have recently modified their holdings of GHDX. Bank of Montreal Can bought a new position in shares of Genomic Health during the second quarter valued at $187,000. Royal Bank of Canada boosted its stake in Genomic Health by 6,543.0% in the first quarter. Royal Bank of Canada now owns 8,503 shares of the company’s stock worth $210,000 after buying an additional 8,375 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Genomic Health during the second quarter worth approximately $270,000. American International Group Inc. boosted its stake in Genomic Health by 3.2% in the second quarter. American International Group Inc. now owns 10,753 shares of the company’s stock worth $278,000 after buying an additional 334 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Genomic Health by 3.0% in the second quarter. Nationwide Fund Advisors now owns 11,932 shares of the company’s stock worth $309,000 after buying an additional 351 shares during the last quarter. Institutional investors and hedge funds own 88.92% of the company’s stock.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.